Flash Finance

Jenburkt Pharmaceuticals Ltd524731Corporate

Pharmaceuticals Latest results: Jun 2026 14 quarters of data
₹995.35
MCap ₹404 Cr · P/E 12.3
Jenburkt Pharmaceuticals Ltd — Stock analysis & AI research Jenburkt Pharmaceuticals Ltd — Live exchange announcements
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹36 Cr
Sales · Jun 2026
-1.4% YoY
₹6 Cr
Operating Profit · Jun 2026
-33.0% YoY
17.0%
OPM % · Jun 2026
-32.0% YoY
₹6 Cr
Net Profit · Jun 2026
-26.4% YoY
₹13.34
EPS · Jun 2026
-24.4% YoY

📝 Jenburkt Pharmaceuticals Ltd — results explained

Quarter ended June 2026 (Q1 FY27)

Jenburkt Pharmaceuticals Ltd reported revenue of ₹36 crore for the quarter ended June 2026 (Q1 FY27), down 1.4% from ₹36 crore in the same quarter last year, and down 21.1% sequentially over the March 2026 quarter.

Net profit fell 26.4% year-on-year to ₹6 crore, from ₹8 crore. Earnings per share (EPS) came in at ₹13.34.

Operating profit stood at ₹6 crore — an operating margin (OPM) of 17.0%, compared with 25.0% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Jenburkt Pharmaceuticals Ltd posted revenue of ₹170 crore, a growth of 11.8% over FY25, with a net profit of ₹35 crore (up 6.1% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹170 crore with a net profit of ₹33 crore.

Valuation snapshot

At the current price of ₹995.35, 524731 has a market capitalisation of ₹404 crore and a trailing P/E of about 12.3.

Within the Pharmaceuticals industry, it is the 15th-largest of the 82 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 46.62%, foreign institutional investors (FIIs) 0.00%, domestic institutional investors (DIIs) 0.12%, public shareholders 53.27% of Jenburkt Pharmaceuticals Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹404 Cr
Current Price ?
₹995.4
P/E ?
12.29below ind
Industry P/E ?
22.40
P/B ?
2.05
P/S ?
2.38
P/FCF ?
31.10
Enterprise Value ?
₹406 Cr
EV/EBITDA ?
10.15
PEG ?
0.82
Earnings Yield ?
9.0%
Dividend Yield ?
1.80%
Profitability & Returns
Sales (TTM) ?
₹170 Cr
OPM ?
23.6%
Profit after tax (TTM) ?
₹33 Cr
EPS (TTM) ?
₹80.97
ROCE ?
27.0%
ROE ?
16.7%
ROA ?
14.6%
Growth
Sales — latest qtr ?
₹36 Cr
PAT — latest qtr ?
₹6 Cr
YoY qtr sales growth ?
-1.4%
YoY qtr profit growth ?
-26.4%
Sales growth (3y) ?
7%
Sales growth (5y) ?
9%
Profit growth (3y) ?
15%
Profit growth (5y) ?
18%
Financial Health
Debt ?
₹2 Cr
Debt to Equity ?
0.01
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
46.62%
Change in promoter holding ?
-0.04%
Pledged percentage ?
N/A
Market
Return 3 months ?
-15.5%
Return 6 months ?
-1.2%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 3529383639334137413646434536 -1.4% -21.1%
Operating Profit 7797109119119137146 -33.0% -57.0%
Other Income 11111122222202 -24.3% —
Interest 00000000000000 — —
Depreciation 10111111111111 -35.9% -35.9%
Profit Before Tax 87108101013101210148147 -32.3% -51.6%
Net Profit 65758710798106116 -26.4% -46.5%
EPS 14.3912.1716.5912.2417.8616.8121.7514.7519.3517.6523.0213.4424.5813.34 -24.4% -45.7%
OPM % 20.0% 24.1% 23.7% 19.4% 25.6% 27.3% 26.8% 24.3% 26.8% 25.0% 28.3% 16.3% 31.1% 17.0% -32.0% -45.3%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹152 Cr ₹170 Cr ₹170 Cr +11.8%
Operating Profit ₹40 Cr ₹43 Cr ₹40 Cr +7.5%
OPM % 26.32% 25.29% 23.61% -3.9%
NPM % 21.71% 20.59% 19.40% -5.2%
Other Income ₹7 Cr ₹6 Cr ₹6 Cr -14.3%
Depreciation ₹4 Cr ₹4 Cr ₹4 Cr +0.0%
Interest ₹0 Cr ₹0 Cr ₹0 Cr —
EBIT ₹36 Cr ₹39 Cr ₹36 Cr +8.3%
PBT ₹45 Cr ₹46 Cr ₹43 Cr +2.2%
Tax — — ₹1 Cr —
Net Profit ₹33 Cr ₹35 Cr ₹33 Cr +6.1%
EPS ₹72.66 ₹78.69 ₹74.38 +8.3%
Material Cost — — ₹8 Cr —
Employee Cost — — ₹13 Cr —
Extraordinary Items — — ₹0 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 4444 +0.0%
Reserves 118141167193 +15.6%
Borrowings 3042 -50.0%
Other Liabilities 16191926 +36.8%
Total Liabilities 141164195226 +15.9%
Fixed Assets 10101519 +26.7%
CWIP 114046 +15.0%
Investments 11172127 +28.6%
Other Assets 119136120133 +10.8%
Total Assets 141164195226 +15.9%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 1782827 -3.6%
Cash from Investing Activity 3-1-17-19 -11.8%
Cash from Financing Activity -21-7-8-9 -12.5%
Net Cash Flow -103-2 -166.7%
Free Cash Flow 156813 +62.5%
CFO/OP 83%49%102%88% -13.7%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 45505053 +6.0%
Inventory Days 92103109154 +41.3%
Days Payable 677510091 -9.0%
Cash Conversion Cycle 707859115 +94.9%
Working Capital Days 31363141 +32.3%
ROCE % 27%26%27%27% +0.0%

👥 Shareholding (latest 4 periods)

Metric Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 46.66%46.65%46.64%46.62% -0.0%
FIIs 0.00%0.00%0.00%0.00% —
DIIs 0.12%0.12%0.12%0.12% +0.0%
Public 53.22%53.24%53.24%53.27% +0.1%
No. of Shareholders 6,8557,1636,9997,103 +1.5%

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUDEEPPHRM Sudeep Pharma ₹1,033.30 11,671 63.3 675 184 34.6% 27.3% — — 26.6% 30.9%
2 SPARC Sun Pharma ₹185.08 6,006 3.8 1,909 1,584 84.7% 83.0% 2512.3% 553.9% 314.1% 59.9%
3 GUJTHEM Gujarat Themis ₹412.60 5,370 92.3 173 48 47.3% 27.8% 8.6% -6.1% 21.6% 23.0%
4 539997 Kwality Pharmaceuticals ₹2,652.10 3,525 34.0 553 81 24.4% 14.6% 35.7% 71.8% 46.3% 113.5%
5 524632 Shukra Pharmaceuticals ₹80.95 2,403 99.9 75 36 65.0% 48.2% 74.0% 130.1% 336.4% 1359.2%
6 FERMENTA Fermenta Biotech ₹475.00 1,362 21.4 501 64 18.9% 12.7% — — -17.9% -30.6%
7 506414 Fermenta Biotech ₹552.60 1,313 27.2 511 59 17.6% 11.5% 11.9% -6.6% -10.4% -56.7%
8 AHCL Anlon Healthcare ₹20.20 1,074 — — — — — — — 163.0% 133.3%
9 541096 Bharat Parenterals ₹1,525.00 1,062 — 323 -30 3.3% -9.3% 1.5% 37.5% -19.2% -309.6%
10 540737 Shree Ganesh ₹796.30 855 66.2 99 15 31.4% 15.6% 0.7% -23.0% -41.8% -67.5%
11 AMANTA Amanta Healthcare ₹197.75 768 52.5 291 15 20.4% 5.0% — — 5.4% -5.6%
12 539730 Fredun Pharmaceuticals ₹827.85 611 10.3 747 44 14.7% 5.9% 40.1% 90.0% 90.2% 88.1%
13 500422 Transchem Ltd-$ ₹38.00 474 10.8 — 4 — — -100.0% -17.8% -100.0% 186.3%
14 HALEOSLABS Haleos Labs ₹1,525.00 461 21.0 324 15 12.6% 4.7% -3.2% -4.9% -11.6% -58.0%
15 524731 Jenburkt Pharmaceuticals ₹865.75 404 11.6 170 33 23.6% 19.4% 11.8% 6.1% -1.4% -26.4%
16 543616 Trident Lifeline ₹279.85 364 14.0 134 24 24.6% 17.9% — — 42.6% 44.2%
17 512600 Astal Laboratories ₹75.00 308 32.3 170 10 8.8% 5.7% 142.9% -9.0% 56.0% 77.4%
18 524828 BDH Industries ₹336.80 300 16.6 100 12 15.3% 11.7% 44.3% 16.6% 20.2% 48.8%
19 500009 Ambalal Sarabhai ₹38.73 297 21.9 206 14 7.1% 6.6% 3.1% 261.1% 8.0% -51.6%
20 532039 Zenotech Laboratories ₹64.90 263 — 45 -3 17.0% -5.6% 1.3% -119.2% 10.1% -146.0%
21 531739 Gennex Laboratories ₹13.87 255 19.0 183 21 14.4% 11.3% 24.9% 15.5% 16.6% -6.9%
22 524790 Everest Organics ₹159.20 252 29.4 191 5 10.3% 2.8% 23.0% 527.7% -10.0% -21.1%
23 530163 Kerala Ayurveda ₹310.20 225 — 125 -26 -14.9% -20.8% 9.0% -16.8% -21.3% -477.8%
24 531569 Sanjivani Paranteral ₹199.95 214 32.7 66 7 15.3% 11.3% -7.6% -14.4% 8.8% 32.7%
25 524636 Oxygenta Pharmaceutical ₹32.25 195 — 135 -14 -5.9% -10.1% 3.3% -70.8% 144.5% 65.6%
❓ Frequently asked questions
What was Jenburkt Pharmaceuticals Ltd's revenue in Q1 FY27?
Jenburkt Pharmaceuticals Ltd reported revenue of ₹36 crore for the quarter ended June 2026 (Q1 FY27), down 1.4% from ₹36 crore in the same quarter last year, and down 21.1% sequentially over the March 2026 quarter.
What was Jenburkt Pharmaceuticals Ltd's net profit in Q1 FY27?
Net profit fell 26.4% year-on-year to ₹6 crore, from ₹8 crore. Earnings per share (EPS) came in at ₹13.34.
What is 524731's market capitalisation and P/E ratio?
At the current price of ₹995.35, 524731 has a market capitalisation of ₹404 crore and a trailing P/E of about 12.3.
Who owns Jenburkt Pharmaceuticals Ltd? (shareholding pattern)
As of Jun 2026, promoters held 46.62%, foreign institutional investors (FIIs) 0.00%, domestic institutional investors (DIIs) 0.12%, public shareholders 53.27% of Jenburkt Pharmaceuticals Ltd.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI